NEUROBLASTOMA

This early-phase study tested a new approach for children with neuroblastoma that did not respond to standard treatments. It used two doses of a radioactive drug (I-MIBG) to target cancer cells, followed by a stem cell transplant to restore healthy blood cells. The goal was to fi…

This study tested whether a smaller dose of radiation can still control high-risk neuroblastoma while causing fewer long-term side effects. 78 children with high-risk neuroblastoma received reduced-dose radiation to the main tumor site. Doctors checked scans and clinical signs to…

This study tested a new antibody (hu14.18K322A) added to standard chemotherapy for 153 children with high-risk neuroblastoma, a serious childhood cancer. The goal was to see if the combination could shrink tumors and improve survival. While the treatment aims to control the disea…

This early-phase trial tested an experimental drug called CUDC-907 in 26 children and young adults (ages 1-21) whose solid tumors, brain tumors, or lymphoma had stopped responding to standard treatments. The main goal was to find safe dosing and identify side effects. Researchers…

This early-phase study tested an oral drug called lorlatinib in 65 children and young adults with ALK-driven neuroblastoma that had come back or not responded to standard treatment. The goal was to find the safest dose and see how the drug works alone or with chemotherapy. The dr…

This early-phase study tested a new treatment for children with high-risk neuroblastoma that did not respond to standard therapy or came back. The approach combines a radioactive drug (131I-MIBG) that targets tumor cells with two chemotherapy drugs (irinotecan and vincristine). T…

This early-phase study tested a new approach for children with high-risk neuroblastoma, a cancer that often returns. Researchers took the patients' own immune cells (T cells) and modified them to better recognize and attack the cancer, while also training them to last longer in t…

This study tested a combination of Hu3F8 (an antibody) and GM-CSF (an immune booster) along with isotretinoin in 59 children with high-risk neuroblastoma who had achieved their first remission. The goal was to see if this immunotherapy could prevent the cancer from coming back. W…

This early-phase study tested an oral powder form of the drug fenretinide in 80 children whose neuroblastoma had returned or resisted standard treatment. The main goals were to find the safest dose and understand side effects. Researchers also looked at how the drug behaves in th…

This early-phase study tested whether immune cells called natural killer (NK) cells could be safely given to children and young adults with solid tumors that did not respond to standard treatments. Sixteen participants received their own activated NK cells, with or without a prot…

This early-stage study tested a type of radiation therapy called PRRT in one child with neuroblastoma that had come back or not responded to standard treatments. The therapy uses a radioactive drug that targets tumor cells. The main goal was to find the safest dose and monitor si…

This study tested a new type of stem cell transplant for children and young adults (ages 2-21) with cancers that came back or didn't respond to treatment. The approach uses a special cell filter to speed up immune recovery after transplant. The main goal was to see if the procedu…

This study tested whether analyzing the genetic makeup of a child's tumor could help doctors choose better treatments. 186 children with cancers that had come back or were not responding to standard therapy took part. The goal was to see if this approach was practical and safe, n…